TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07765511: A Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Macupatide Monotherapy, and Macupatide in Combination With Eloralintide, in Japanese Participants With Obesity or Over

Sponsor: Eli Lilly and Company · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 60 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$677,280

Rescue Site Savings

+$451,520

Unlock Full NCT07765511 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07765511 Rescue Dossier →